Lister Troy 4
4 · Verve Therapeutics, Inc. · Filed Jan 10, 2025
Insider Transaction Report
Form 4
Lister Troy
Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2025-01-08+225,000→ 225,000 totalExercise: $6.01Exp: 2035-01-07→ Common Stock (225,000 underlying) - Award
Restricted Stock Units
2025-01-08+40,000→ 40,000 total→ Common Stock (40,000 underlying)
Footnotes (3)
- [F1]The option was granted on January 8, 2025. 25% of the shares underlying the option will vest on January 8, 2026, and the remainder are scheduled to vest in equal monthly installments thereafter until January 8, 2029.
- [F2]Each restricted stock unit represents a contingent right to receive one share of common stock.
- [F3]On January 8, 2025, the reporting person was granted restricted stock units, vesting in three equal annual installments, beginning on April 1, 2026, and the remaining two installments vesting on April 1, 2027 and April 1, 2028.